Abolis Biotechnologies, an Évry-Courcouronnes, France-based company which specializes in industrial solutions using microorganisms, raised €35M in funding.
Backers included L’Oréal’s venture capital fund BOLD, DeepTech & Climate Fonds, and Evonik Venture Capital as lead investors, as well as Clay Capital, ICOS Capital and Liberset.
The company intends to use the funds to accelerate its expansion into global markets and accelerate its research and development efforts to bring its own portfolio of ingredients, which will be industrialized with partners, to the market.
Led by CEO Cyrille Pauthenier, Abolis combines expertise in biology, fermentation, IT, robotics, analytics and industrial property to innovate industries – from food to healthcare, cosmetics and chemicals. It leverages biotechnologies and the potential of micro-organisms to develop bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients.
The investment was accompanied by the signing of a new strategic industrial partnership between Abolis, L’Oréal and Evonik to bring selected innovations to market, for healthcare, cosmetic and chemical sectors.
FinSMEs
13/09/2024